首页> 外文OA文献 >Upper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate: mobile 2-year analysis

【2h】

Upper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate: mobile 2-year analysis

机译：每月一次和每天一次口服伊班膦酸的上消化道安全性和耐受性概况：流动性2年分析

页面导航

摘要
著录项
相似文献
相关主题

摘要

Peer reviewed

机译：同行评审

著录项

作者
Czerwinski, E.; Nuti, R.; Greenwald, M.; Burdeska, A.; Leigh, C.; Reginster, Jean-Yves;
展开▼
作者单位

展开▼
年度 2006
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. [J] . Emkey R, Delmas PD, Bolognese M, Clinical therapeutics . 2009,第4期

机译：每月一次口服伊班膦酸（150 mg）和每周一次口服阿仑膦酸盐（70 mg）的疗效和耐受性：伊班膦酸每月口服治疗骨质疏松症的干预措施（MOTION）的其他结果。
2. Intravenous and oral ibandronate have better safety and tolerability profiles than zoledronic acid: evidence from comparative phase III trials [J] . B.Bergstr?m, Lichinitser, S.Tjulandin, European Journal of Cancer Supplements . 2006,第2期

机译：静脉和口服伊班膦酸比唑来膦酸具有更好的安全性和耐受性：比较III期试验的证据
3. Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. [J] . Ettinger MP, Felsenberg D, Harris ST, The Journal of rheumatology . 2005,第10期

机译：每日口服和间歇性伊班膦酸盐的安全性和耐受性不受年龄的影响。
4. Locomotion characteristics of soft mobile robot platform for upper gastrointestinal (UGI) fluoroscopic examination [C] . Mohamed Najib Ribuan, Suichi Wakimoto, Koichi Suzumori, IEEE/SICE International Symposium on System Integration . 2015

机译：用于上消化道（UGI）荧光检查的软移动机器人平台的运动特性
5. Analysis of functional gene profiles in the pancreatic cancer oral microbiome. [D] . Cookson, Garrett Lee. 2016

机译：胰腺癌口腔微生物组中功能基因谱分析。
6. Upper gastrointestinal safety and tolerability of oral alendronate: A meta-analysis [O] . MANRU ZHOU, YAYUAN ZHENG, JIN LI, -1

机译：口服阿仑膦酸盐的上消化道安全性和耐受性：一项荟萃分析
7. Upper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate is similar in postmenopausal osteoporosis: 1-year results from MOBILE [O] . Adami, Silvio, Tanko, L. B., Nuti, R., 2005

机译：绝经后骨质疏松症每月一次和每日口服伊班膦酸的上消化道安全性和耐受性特征相似：MOBILE的1年结果

Upper gastrointestinal safety and tolerability profile of once-monthly and daily oral ibandronate: mobile 2-year analysis

摘要

著录项

相似文献

相关主题

期刊订阅